← Leaderboards
Garrett E Bergman
Octagen Corporation
$298,556
Attributed
$298,556
Total exposure
9
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,123,556 · 10
By mechanism
R44$825,000 · 7
R43$198,556 · 2
R41$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Octagen Corporation
Same institution · by research overlap
Others in their field
Top investigators on “Coagulation Factor Viii”
- Randal J. Kaufman · Indiana University Indianapolis$15,342,889
- John S. Lollar · Emory University$13,776,513
- Roland W. Herzog · Indiana University Indianapolis$13,370,934
- Mortimer Poncz · University Of Pennsylvania$11,034,768
- David Ginsburg · University Of Michigan At Ann Arbor$9,880,157
- Nicholas L Smith · University Of Washington$8,276,711
Research focus
Coagulation Factor ViiiHemophilia AsLaboratory MouseRecombinant ProteinsProtein EngineeringDrug Design /Synthesis /ProductionHuman SubjectNeutralizing AntibodyAntigensBiotherapeutic AgentAntigen Antibody ReactionDrug Screening /EvaluationEnzyme Linked Immunosorbent AssayImmunologic Substance Development /PreparationMacaca FascicularisPatient Oriented ResearchHemostaticsClearance RateImmunogeneticsTransfection /Expression VectorChemical BindingVon Willebrand FactorMonoclonal AntibodyBlood Disorder Chemotherapy
Grant awards (11)
OBI-1 - 305 Rescue theraphy, cong &acquired, all else failed$0
R44 · FY2005 · HL
OBl-1 - 201: Dosing regimen, cogential hemophilia, non-life threatening bleeding$0
R44 · FY2005 · HL
OBl-1 301:Pivotal study, congential hemophilia, all bleeding categories$0
R44 · FY2005 · HL
OBI-1 - 302 Pivotal study, acquired hemophilia, all bleeding categories$0
R44 · FY2005 · HL
OBI-1 - 303 Surgical study, congenital hemophilia$0
R44 · FY2005 · HL
OBI-1 - 304 Surgical study, acquired hemophilia$0
R44 · FY2005 · HL
Low Immunogenicity Factor VIII$100,000
R43 · FY2004 · HL
Low Antigenicity Factor VIII$413,000
R44 · FY2002 · HL
Gene Therapy for Hemophilia A$100,000
R41 · FY2002 · HL
Low Antigenicity Factor VIII$412,000
R44 · FY2001 · HL
LOW ANTIGENICITY FACTOR VIII$98,556
R43 · FY2000 · HL